GSK
GSK plc
NYSE · Healthcare · Drug Manufacturers - General · GB
$49.89
−1.93%Year over year
Reported trailing growth
- Revenue
- +3.2%
- EBITDA
- +0.6%
- EBIT
- -8.7%
- EPS
- -11.8%
- Free cash flow
- +17.2%
- Operating cash flow
- +1.7%
Forward estimates
Based on analyst estimates
- Revenue
- +5.0%
- EBITDA
- +64.3%
- EPS
- +56.1%
Three-year CAGR
- Revenue
- +3.7%
- EBITDA
- +6.5%
- EBIT
- +9.0%
- Net income
- -27.4%
- EPS
- -27.6%
- Free cash flow
- -4.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026